Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Pathology

Internal Medicine

Cardiology

Urology

Show all topics

DOI

10.1016/s0140-6736(15)00257-3

License

CC-BY

Other Formats

PDF